What You Should Know:
- C2i Genomics, a cancer intelligence company launches its C2inform minimal residual disease (MRD) test across Europe, after obtaining CE-IVD marking in the EU, UK and Switzerland. The company also announced the completion of several clinical trials across the globe, including leading cancer centers in Europe, U.S. and Singapore.
- The new clinical data will be presented at the 2022 American Association for Cancer Research (AACR) annual meeting in New Orleans,
Read More
Clinical Trials | News, Analysis, Insights - HIT Consultant
Labcorp & Medidata to Co-Develop Digital Biomarkers & Expand Decentralized Clinical Trials
What You Should Know:
- Medidata, a Dassault Systèmes company, today announced that Labcorp, a leading global life sciences company, has selected Medidata's technology platform to extend their 14-year partnership, the foundation of their initiative to co-develop digital biomarkers and expand the use and functionality of decentralized clinical trials. Labcorp Drug Development has developed its offerings on Medidata technologies, starting with Rave EDC
Read More
VivoSense Raises $25M for Wearable Sensor Biomarkers to Advance Clinical Trials
What You Should Know:
- VivoSense, an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data raises $25 Million in Series A funding.
- The financing will accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments. VivoSense will also use this financing to expand and refine its informatics platform for data analysis from wearable and connected technologies to deliver validated digital
Read More
COTA Promotes Miruna Sasu to President and CEO
What You Should Know:
- COTA, Inc., an oncology real-world data and analytics company, announced today that Miruna Sasu, Ph.D., MBA, has been appointed president and chief executive officer.
- Since April 2021 when she was hired as the company’s chief strategy officer, Miruna has helped spearhead a series of research collaborations focused on investigating racial disparities in cancer care and the drug development process, including partnerships with the University of Chicago
Read More
Tempus Launches Pathology-Driven AI Platform
What You Should Know:
- Tempus, a provider of artificial intelligence and precision medicine, today announced the launch of Edge, an innovative platform that allows pathologists to access developing AI models intended to identify specimens with potentially actionable biomarkers using a single hematoxylin and eosin stain (H&E) slide.
- With access to over 50 petabytes of de-identified multimodal data, Tempus is developing AI models with the aim to identify patients who would
Read More
Applied XL Raises $3.5M for Real-Time Data Tracking Platform
What You Should Know:
- Applied XL, a real-time information company tracking disruptions to the health of people, places, and the planet, today announced it had raised $3.5 million in seed funding led by Hearst Ventures with the participation of the Boston Globe Media Partners and STAT, which are owned by the Henry family.
- The latest round brings Applied XL’s total funds raised to date to $5 million in the last 12 months. The company will use the new funding to scale its first vertical
Read More
Day 3 HIMSS Roundup: Glooko Acquires DIABNEXT, GE Healthcare/AliveCor Integration
Venture Capital, Private Equity, Mergers & Acquisitions (M&A) Activity
Glooko Acquires DIABNEXT® to Expand Diabetes Offerings in France
Glooko, a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions, today announced the acquisition of DIABNEXT, a Paris-based company whose digital health platform helps people with diabetes better manage their conditions and connects to their healthcare providers, so they can
Read More
Black Female Co-founders CancerIQ Raises $14M to Improve Cancer Early Detection and Prevention
What You Should Know:
- CancerIQ, a Chicago-based platform powering early cancer detection and prevention across broad patient populations, announced today it closed a $14M Series B financing round.
- The Series B round was co-led by Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures with participation from McKesson Ventures, OSF Ventures (the investment arm of OSF HealthCare, a current CancerIQ customer), and HealthX Ventures.
Inequality in
Read More
How Support Automation Enhances Clinical Trial Management
The life of a clinical study relies on data from documentation, meetings, emails and calls; all of which can be overwhelming for patients, clinical trial teams and associates. Although mundane, documenting, executing and collecting data is crucial to move a trial from phase to phase.
Clinical trial teams face a multitude of competing priorities, from evaluating hundreds of potential patients to maintaining compliance and recording patient progress. No aspect or step can be neglected for a
Read More
Helping Clinical Trial Sites Improve Study Recruitment and Retention
The clinical trial industry is, once again, at an uncertain crossroads. And while it might be assumed that the outsized impact of the COVID-19 pandemic has resulted in the inability to recruit patients for trials, it is instead, a challenge generated, over time, by the industry itself. Thankfully, there is an opportunity to change course.
It’s no secret that research studies and clinical trial sites struggle with recruitment. In fact, the National Institutes of Health (NIH) states
Read More
